Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

NCT04982393 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT04982393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04982393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
Lead sponsor
Alnylam Pharmaceuticals
Phase
Observational
Overall status
Active, not recruiting
Start date
December 13, 2021
Completion date
January 2, 2029
Enrollment
207 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

primary hyperoxaluria type 1